GSTM3

Across TCGA pan-cancer cohorts, GSTM3 mass-spec protein differs between tumor and matched normal tissue in 7 of 18 cancer types tested, making tumor–normal expression one of GSTM3’s most consistent transcriptional readouts.

The strongest signal is observed in clear cell renal cell carcinoma (CCRCC), where GSTM3 mass-spec protein is repressed in tumor relative to normal tissue. In most cancer types GSTM3 is over-expressed in tumor, although a few such as CCRCC and COAD show the opposite, repressed pattern.

CCRCC, COAD, and LUAD are the cancer types where GSTM3 tumor–normal differential expression is most reproducible.

mass-spec protein tumor vs normal associations by lineage

Ranked by sampling consensus. Fold-change is the tumor-versus-normal difference in GSTM3 mass-spec protein (log₂); positive values indicate higher expression in tumor. p-values are from the differential-expression test.

Lineage	Gender	Stage	Fold-change	p	Sampling consensus
CCRCC	Male	IV	−1.940	<.001	12	view →
COAD	Male	III,IV	−1.621	<.001	11	view →
LUAD	Female	III,IV	−1.245	<.001	9	view →
PDAC	Male	All	−0.943	<.001	7	view →
HNSC	All	II,III,IV	−0.683	<.001	7	view →
OV	All	All	−1.228	<.001	2	view →
LSCC	Female	All	−0.699	.003	1	view →

Pink = over-expressed in tumor, green = repressed in tumor. Showing the 7 strongest of 7 lineages.

GSTM3–CCRCC

Open the CCRCC breakdown →